Citations

Clear

959 citation(s) found for "Service, F J".

Calmodulin mutations and life-threatening cardiac arrhythmias: insights from the International Calmodulinopathy Registry
Crotti, Lia , Spazzolini, Carla , Tester, David J. , Ghidoni, Alice , Baruteau, Alban‐Elouen , Beckmann, Britt Maria , Behr, Elijah R. , Bennett, Jeffrey S. , Bezzina, Connie R. , Bhuiyan, Zahurul A. , Çeliker, Alpay, Cerrone, Marina , Etheridge, Susan P. , Fatah, Meena , García‐Pavía, Pablo , Hamilton, Robert M. , Al‐Hassnan, Zuhair N. , Horie, Minoru , Jiménez‐Jáimez, Juan , Kanter, Ronald J. , Kaski, Juan Pablo , Kotta, Maria‐Christina , Lahrouchi, Najim , Makita, Naomasa , Norrish, Gabrielle , Odland, Hans Henrik , Ohno, Seiko , Papagiannis, John , Parati, Gianfranco , Sekarski, Nicole , Tveten, Kristian , Vatta, Matteo , Wilde, Arthur A.M. , Wojciak, Julianne, Ackerman, Michael J. , Crotti, Lia , Makita, Naomasa , Horie, Minoru , Behr, Elijah Raphael , Kotta, Maria-Christina , Baruteau, Alban-Elouen , Garcia-Pavia, Pablo , Cerrone, Marina , Hamilton, Robert , Kaski, Juan P , Odland, Hans H , Sekarski, Nicole , Bezzina, Connie R , Spazzolini, Carla , Çeliker, Alpay , Dagradi, Federica , Ferrari, Gaetano Maria De , Al-Ghamdi, Saleh, Ohno, Seiko , Webster, Gregory , George, Alfred L. , Schwartz, Peter J.

Mayo Clinic

European Heart Journal | April 29, 2019 | Volume: 40 | Issue: 35 | Pages: 2964-2975

10.1093/eurheartj/ehz311 | PMID 31170290 Get It

Abstract Aims Calmodulinopathies are rare life-threatening arrhythmia syndromes which affect mostly young individuals and are, caused by mutations in any of the three genes (CALM 1–3) that encode identical calmodulin proteins. We established the International Calmodulinopathy Registry (ICalmR) to understand the natural history, clinical features, and response to therapy of patients with a CALM-mediated arrhythmia syndrome. Methods and results A dedicated Case Report File was created to collect demographic, clinical, and genetic information. ICalmR has enrolled 74 subjects, with a variant in the CALM1 (n = 36), CALM2 (n = 23), or CALM3 (n = 15) genes. Sixty-four (86.5%) were symptomatic and the 10-year cumulative mortality was 27%. The two prevalent phenotypes are long QT syndrome (LQTS; CALM-LQTS, n = 36, 49%) and catecholaminergic polymorphic ventricular tachycardia (CPVT; CALM-CPVT, n = 21, 28%). CALM-LQTS patients have extremely prolonged QTc intervals (594 ± 73 ms), high prevalence (78%) of life-threatening arrhythmias with median age at onset of 1.5 years [interquartile range (IQR) 0.1–5.5 years] and poor response to therapies. Most electrocardiograms (ECGs) show late onset peaked T waves. All CALM-CPVT patients were symptomatic with median age of onset of 6.0 years (IQR 3.0–8.5 years). Basal ECG frequently shows prominent U waves. Other CALM-related phenotypes are idiopathic ventricular fibrillation (IVF, n = 7), sudden unexplained death (SUD, n = 4), overlapping features of CPVT/LQTS (n = 3), and predominant neurological phenotype (n = 1). Cardiac structural abnormalities and neurological features were present in 18 and 13 patients, respectively. Conclusion Calmodulinopathies are largely characterized by adrenergically-induced life-threatening arrhythmias. Available therapies are disquietingly insufficient, especially in CALM-LQTS. Combination therapy with drugs, sympathectomy, and devices should be considered.
Family Medicine Patients Have Shorter Length of Stay When Cared for on a Family Medicine Inpatient Service
Garrison, Gregory M. , Keuseman, Rachel , Boswell, Christopher L. , Horn, Jennifer L. , Nielsen, Nathaniel T., Nielsen, Megan , Keuseman, Rachel L, Nielsen, Megan L, Nielsen, Megan L.

Mayo Clinic

Journal of Primary Care & Community Health | April 27, 2019 | Volume: 10 | Issue: No issue available | Pages: No page available

10.1177/2150132719840517 | PMID 31027438 Get It

Introduction: Hospitalists have been shown to have shorter lengths of stays than physicians with concurrent outpatient practices. However, hospitalists at academic medical centers may be less aware of local resources that can support the hospital to home transition for local primary care patients. We hypothesized that local family medicine patients admitted to a family medicine inpatient service have shorter length of stay than those admitted to general hospitalist services which also care for tertiary patients at an academic medical center. Methods: A retrospective cohort study was conducted at an academic medical center with a department of family medicine providing primary care to over 80 000 local patients. A total of 3100 consecutive family medicine patients admitted to either the family medicine inpatient service or a general medicine inpatient service over 3 years were studied. The primary outcome was length of stay, which was adjusted using multivariate linear regression for demographics, prior utilization, diagnosis, and disease severity. Results: Adjusted length of stay was 33% longer (95% CI 24%-44%) for local family medicine patients admitted to general medicine inpatient services as compared with the family medicine inpatient service. Readmission rates within 30 days were not different (19% vs 16%, P = .14). Conclusions: Local primary care patients were safely discharged from the hospital sooner on the family medicine inpatient service than on general medicine inpatient services. This is likely because the family physicians staffing their inpatient service are more familiar with outpatient resources that can be effectively marshaled to help local patients with the transition from hospital to home.
Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest
Werf, Christian van der , Lieve, Krystien V.V. , Bos, J. Martijn , Lane, Conor M. , Rosés‐Noguer, Ferran , Aiba, Takeshi , Wada, Yuko , Ingles, Jodie , Leren, Ida S. , Rudic, Boris , Maltret, Alice , Sacher, Frédéric , Skinner, Jonathan R. , Roston, Thomas M. , Tfelt‐Hansen, Jacob , Swan, Heikki, Robyns, Tomas , Ohno, Seiko , Roberts, Jason D. , Berg, Maarten P. van den , Kammeraad, Janneke A.E. , Blom, Nico A, Behr, Elijah R. , Borggrefe, Martin , Haugaa, Kristina H. , Semsarian, Christopher , Horie, Minoru , Till, Janice, Ackerman, Michael J. , Wilde, Arthur A.M. , Horie, Minoru , Behr, Elijah Raphael , Bos, Johan M , Tfelt-Hansen, Jacob , Skinner, Jonathan R , van den Berg, Maarten P , Robyns, Tomas , Haugaa, Kristina , Wada, Yuko , van der Werf, Christian , Rosés-Noguer, Ferran , Denjoy, Isabelle , Aiba, Takeshi , Schwartz, Peter J. , Krahn, Andrew D. , Ohno, Seiko , Probst, Vincent , Kannankeril, Prince J. , Blom, Nico A. , Shimizu, Wataru , Leenhardt, Antoine , Ingles, Jodie , Lieve, Krystien V

Mayo Clinic

European Heart Journal | April 26, 2019 | Volume: 40 | Issue: 35 | Pages: 2953-2961

10.1093/eurheartj/ehz309 | PMID 31145795 Get It

Abstract Aims In patients with catecholaminergic polymorphic ventricular tachycardia (CPVT), implantable cardioverter-defibrillator (ICD) shocks are sometimes ineffective and may even trigger fatal electrical storms. We assessed the efficacy and complications of ICDs placed in patients with CPVT who presented with a sentinel event of sudden cardiac arrest (SCA) while undiagnosed and therefore untreated. Methods and results We analysed 136 patients who presented with SCA and in whom CPVT was diagnosed subsequently, leading to the initiation of guideline-directed therapy, including β-blockers, flecainide, and/or left cardiac sympathetic denervation. An ICD was implanted in 79 patients (58.1%). The primary outcome of the study was sudden cardiac death (SCD). The secondary outcomes were composite outcomes of SCD, SCA, appropriate ICD shocks, and syncope. After a median follow-up of 4.8 years, SCD had occurred in three patients (3.8%) with an ICD and none of the patients without an ICD (P = 0.1). SCD, SCA, or appropriate ICD shocks occurred in 37 patients (46.8%) with an ICD and 9 patients (15.8%) without an ICD (P < 0.0001). Inappropriate ICD shocks occurred in 19 patients (24.7%) and other device-related complications in 22 patients (28.9%). Conclusion In previously undiagnosed patients with CPVT who presented with SCA, an ICD was not associated with improved survival. Instead, the ICD was associated with both a high rate of appropriate ICD shocks and inappropriate ICD shocks along with other device-related complications. Strict adherence to guideline-directed therapy without an ICD may provide adequate protection in these patients without all the potential disadvantages of an ICD.
Stereotactic radiosurgery for idiopathic glossopharyngeal neuralgia: an international multicenter study
Kano, Hideyuki , Urgošík, Dušan, Liščák, Roman , Pollock, Bruce E. , Cohen‐Inbar, Or , Sheehan, Jason P. , Barnett, Gene H. , Mathieu, David , Sisterson, Nathaniel , Lunsford, L. Dade , Mathieu, David , Sharma, Mayur , Silva, Danilo

Mayo Clinic

Journal of Neurosurgery | April 19, 2019 | Volume: 125 | Issue: Supplement_1 | Pages: 147-153

10.3171/2016.7.gks161523 | PMID 27903192 Get It

OBJECTIVEThe goal of this study was to evaluate the outcomes of Gamma Knife stereotactic radiosurgery (SRS) when used for patients with intractable idiopathic glossopharyngeal neuralgia.METHODSSix participating centers of the International Gamma Knife Research Foundation identified 22 patients who underwent SRS for intractable glossopharyngeal neuralgia between 1998 and 2015. The median patient age was 60 years (range 34–83 years). The median duration of symptoms before SRS was 46 months (range 1–240 months). Three patients had unsuccessful prior surgical procedures, including microvascular decompression (MVD) (n = 2) and balloon compression (n = 1). The radiosurgical target was the glossopharyngeal meatus. The median maximum dose was 80 Gy.RESULTSThe median follow-up was 45 months after SRS (range 6–120 months). Twelve patients (55%) had < 4 years of follow-up. Thirteen patients (59%) had initial complete pain relief at a median of 12 days after SRS (range 1–60 days). Three patients (14%) had partial pain relief at a median of 70 days after SRS (range 60–90 days). Six patients (27%) had no pain relief. Among 16 patients with initial pain relief, 5 maintained complete pain relief without medication (Barrow Neurological Institute [BNI] pain intensity score Grade I), 1 maintained occasional pain relief without medication (BNI Grade II), 3 maintained complete pain relief with medication (BNI Grade IIIb), and 7 patients had pain recurrence at a median of 20 months after SRS (range 6–120 months). The rates of maintenance of adequate pain relief (BNI Grades I–IIIb) were 63% at 1 year, 49% at 2 years, 38% at 3 years, 38% at 5 years, and 28% at 7 years. When 7 patients without pain recurrence within 4 years of follow-up were excluded, the rates of maintenance of adequate pain relief were 38% at 5 years and 28% at 7 years. Ten patients required additional procedures (MVD, n = 4; repeat SRS, n = 5; glossopharyngeal nerve block, n = 1). Four of 5 patients who underwent repeat SRS maintained pain relief (BNI Grade I, n = 3; and BNI Grade IIIb, n = 1). No adverse effects of radiation were observed after a single SRS. Two patients developed hyperesthesia in the palatoglossal arch 5 and 8 months after repeat SRS, respectively.CONCLUSIONSStereotactic radiosurgery for intractable, medically refractory glossopharyngeal neuralgia provided lasting pain reduction in 55% of patients after 1 or 2 SRS procedures. Patients who had a poor response or pain recurrence may require additional procedures such as repeat SRS, MVD, nerve blocks, or nerve section. No patient developed changes in vocal cord function or swallowing disorders after SRS in this study.
Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis
Black, Christopher J. , Camilleri, Michael , Earnest, David L., Houghton, Lesley A. , Ford, Alexander C. , Camilleri, M , Ford, Alexander C , Houghton, L A , Black, Christopher J , Burr, Nicholas Ewin , Quigley, Eamonn M.M. , Moayyedi, Paul

Mayo Clinic

Gut | April 17, 2019 | Volume: 69 | Issue: 1 | Pages: 74-82

10.1136/gutjnl-2018-318160 | PMID 30996042 Get It

Objective Over half of patients with IBS have either diarrhoea (IBS-D) or a mixed stool pattern (IBS-M). The relative efficacy of licenced pharmacological therapies is unclear in the absence of head-to-head trials. We conducted a network meta-analysis to resolve this uncertainty. Design We searched MEDLINE, Embase, Embase Classic, the Cochrane central register of controlled trials, and Clinicaltrials.gov through January 2019 to identify randomised controlled trials (RCTs) assessing the efficacy of licenced pharmacological therapies (alosetron, eluxadoline, ramosetron and rifaximin) in adults with IBS-D or IBS-M. Trials included in the analysis reported a dichotomous assessment of overall response to therapy, and data were pooled using a random effects model. Efficacy and safety of all pharmacological therapies were reported as a pooled relative risk with 95% CIs to summarise the effect of each comparison tested. Treatments were ranked according to their p score. Results We identified 18 eligible RCTs (seven alosetron, five ramosetron, two rifaximin and four eluxadoline), containing 9844 patients. All were superior to placebo for the treatment of IBS-D or IBS-M at 12 weeks, according to the Food and Drug Administration (FDA)-recommended endpoint for trials in IBS. Alosetron 1 mg twice daily was ranked first for efficacy, based on the FDA-recommended composite endpoint of improvement in both abdominal pain and stool consistency, effect on global symptoms of IBS and effect on stool consistency. Ramosetron 2.5µg once daily was ranked first for effect on abdominal pain. Total numbers of adverse events were significantly greater with alosetron 1 mg twice daily and ramosetron 2.5µg once daily, compared with placebo. Rifaximin 550 mg three times daily ranked first for safety. Constipation was significantly more common with all drugs, except rifaximin 550 mg three times daily. Conclusion In a network meta-analysis of RCTs of pharmacological therapies for IBS-D and IBS-M, we found all drugs to be superior to placebo, but alosetron and ramosetron appeared to be the most effective.
Determining the relationship between hot flushes and LH pulses in menopausal women using mathematical modelling
Prague, Julia , Clarke, Sophie , Comninos, Alexander , Abbara, Ali , Jayasena, Channa , Roberts, Rachel , Yang, Lisa, Veldhuis, Johannes D. , Tsaneva‐Atanasova, Krasimira , McArdle, Craig A. , Dhillo, Waljit S. , Voliotis, Margaritis , Jayasena, Channa N

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | April 15, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1210/jc.2018-02797 | PMID 30985867 Get It

Letter: meta‐analysis of prebiotics, probiotics, synbiotics and antibiotics in IBS. Authors’ reply
Ford, Alexander C. , Harris, Lucinda A. , Lacy, Brian E. , Quigley, Eamonn M.M. , Ford, Alexander C , Quigley, Eamonn M M , Moayyedi, Paul

Mayo Clinic

Alimentary Pharmacology & Therapeutics | April 12, 2019 | Volume: 49 | Issue: 9 | Pages: 1254-1255

10.1111/apt.15234 | PMID 30977174 Get It

Linked ContentThis article is linked to Ford et al and Sun et al papers. To view these articles, visit https://doi.org/10.1111/apt.15001 and https://doi.org/10.1111/apt.15230.
Targeted Sequencing Study to Uncover Shared Genetic Susceptibility Between Peripheral Artery Disease and Coronary Heart Disease—Brief Report
Safarova, Maya , Fan, Xiao , Austin, Erin , Zuydam, Natalie Van, Hopewell, Jemma C. , Schaid, Daniel J. , Safarova, Maya S, Austin, Erin E, Hopewell, Jemma C , Kullo, Iftikhar J.

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | April 11, 2019 | Volume: 39 | Issue: 6 | Pages: 1227-1233

10.1161/atvbaha.118.312128 | PMID 31070467 Get It

Objective— It is unclear to what extent genetic susceptibility variants are shared between peripheral artery disease (PAD) and coronary heart disease (CHD), both manifestations of atherosclerotic vascular disease. We investigated whether common and low-frequency/rare variants in loci associated with CHD are also associated with PAD. Approach and Results— Targeted sequencing of 41 genomic regions associated with CHD in genome-wide association studies was performed in 1749 PAD cases (65±11 years, 61% men) and 1855 controls (60±11 years, 56% men) of European ancestry. PAD cases had a resting/postexercise ankle-brachial index ≤0.9, or history of lower extremity revascularization; controls had no history of PAD. We tested the association of common (defined as minor allele frequency ≥5%) variants with PAD assuming an additive genetic model with adjustment for age and sex. To identify low-frequency/rare variants (minor allele frequency <5%) associated with PAD, we conducted gene-level analyses using sequence kernel association test and permutation test. After Bonferroni correction, we found common variants in SH2B3, ABO , and ZEB2 to be associated with PAD ( P <4.5×10 −5 ). At the gene level, the strongest associations were for LPL and SH2B3 . Conclusions— Targeted sequencing of 41 genomic regions associated with CHD revealed several common variants/genes to be associated with PAD, highlighting the basis of shared genetic susceptibility between CHD and PAD.
How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy
Grimm, Max‐Joseph, Respondek, Gesine , Stamelou, María , Arzberger, Thomas, Ferguson, Leslie W. , Gelpí, Ellen , Irwin, David J. , Pantelyat, Alexander , Rajput, Alex, Roeber, Sigrun, Troakes, Claire , Antonini, Angelo , Eimeren, Thilo van , Kassubek, Jan , Xiong, Chengjie , Meissner, Wassilios G. , Oertel, Wolfgang H. , Piot, Ines , Boxer, Adam L. , Golbe, Lawrence I. , Josephs, Keith A. , Morris, Huw R. , Whitwell, Jennifer L. , Compta, Yaroslau , Corvol, Jean‐Christophe , Rowe, James B. , Höglinger, Günter U. , Group, for the Movement Disorder Society‐endorsed PSP Study, Irwin, David J , Antonini, Angelo , Meissner, Wassilios G , Lang, Anthony E , Rowe, James B , Höglinger, Günter U , Corvol, Jean-Christophe , Xiong, Chengjie , Gelpi, Ellen , Pantelyat, Alex , Giese, Armin , Grossman, Murray , Swieten, John C. van , Bhatia, Kailash P. , Colosimo, Carlo , Nilsson, Christer, Poewe, Werner H , Wenning, Gregor K. , Litvan, Irene , Lang, Anthony E. , Group, for the Movement Disorder Society‐endorsed PSP Study, Troakes, Claire , Morris, Huw R , van Eimeren, Thilo

Mayo Clinic

Movement Disorders | March 19, 2019 | Volume: 34 | Issue: 8 | Pages: 1228-1232

10.1002/mds.27666 | PMID 30884545 Get It

Abstract Background The Movement Disorder Society criteria for progressive supranuclear palsy define diagnostic allocations, stratified by certainty levels and clinical predominance types. We aimed to study the frequency of ambiguous multiple allocations and to develop rules to eliminate them. Methods We retrospectively collected standardized clinical data by chart review in a multicenter cohort of autopsy‐confirmed patients with progressive supranuclear palsy, to classify them by diagnostic certainty level and predominance type and to identify multiple allocations. Results Comprehensive data were available from 195 patients. More than one diagnostic allocation occurred in 157 patients (80.5%). On average, 5.4 allocations were possible per patient. We developed four rules for Multiple Allocations eXtinction (MAX). They reduced the number of patients with multiple allocations to 22 (11.3%), and the allocations per patient to 1.1. Conclusions The proposed MAX rules help to standardize the application of the Movement Disorder Society criteria for progressive supranuclear palsy. © 2019 International Parkinson and Movement Disorder Society